Preparation and evaluation of floating risedronate sodium-Gelucire® 43/01 formulations

被引:21
作者
Chauhan, H [1 ]
Shimpi, S [1 ]
Mahadik, KR [1 ]
Paradkar, A [1 ]
机构
[1] Bharati Vidyapeeth Deemed Univ, Dept Pharmaceut, Poona Coll Pharm, Pune 411038, Maharashtra, India
关键词
risedronate sodium; single-unit; multi-unit; drug release; Gelucire; hot stage microscopy; floating;
D O I
10.1080/03639040500271837
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Single and multi-unit floating matrices of risedronate sodium were prepared using Gelucire(R) 43/01 by melt solidification and melt granulation technique, respectively. The controlled release floating matrices were evaluated for in vitro and in vivo floating ability and in vitro drug release. Effect of aging on Gelucire(R) 43/01 was evaluated by hot stage microscopy (HSM), scanning electron microscopy (SEM), differential scanning calorimetry (DSC), in vitro floating ability, and in vitro drug release. Multi-unit system obtained has shown initial burst release, which was suppressed in single unit system. Both single- as well as multi-unit systems showed increase in rate of drug release on aging due to changes in the properties of the Gelucire(R) 43/01. Multi-unit matrices obtained by melt granulation were relatively easier for scale up and advantageous if the initial burst release does not cause any significant clinical adversity.
引用
收藏
页码:851 / 860
页数:10
相关论文
共 28 条
[1]  
AHLGREN N, 2000, Patent No. 6117452
[2]  
Ainaoui A, 1997, J POLYM ENG, V17, P245
[3]   Modelling the plasma drug level with oral controlled release dosage forms with lipidic Gelucire [J].
Aïnaoui, A ;
Vergnaud, JM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1998, 169 (02) :155-162
[4]   An investigation into the structure and bioavailability of α-tocopherol dispersions in Gelucire 44/14 [J].
Barker, SA ;
Yap, SP ;
Yuen, KH ;
McCoy, CP ;
Murphy, JR ;
Craig, DQM .
JOURNAL OF CONTROLLED RELEASE, 2003, 91 (03) :477-488
[5]   SODIUM LAURYL SULFATE INCREASES TILUDRONATE PARACELLULAR TRANSPORT USING HUMAN EPITHELIAL CACO-2 MONOLAYERS [J].
BOULENC, X ;
BREUL, T ;
GAUTIER, JC ;
SAUDEMON, P ;
JOYEUX, H ;
ROQUES, C ;
BERGER, Y ;
FABRE, G .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 123 (01) :71-83
[6]  
Bowtle V, 2000, PHARM TECHNOL EUR, V12, P20
[7]   Esophagitis associated with the use of alendronate [J].
deGroen, PC ;
Lubbe, DF ;
Hirsch, LJ ;
Daifotis, A ;
Stephenson, W ;
Freedholm, D ;
PryorTillotson, S ;
Seleznick, MJ ;
Pinkas, H ;
Wang, KK .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (14) :1016-1021
[8]   The management of Paget's disease of bone [J].
Delmas, PD ;
Meunier, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 336 (08) :558-566
[9]   INVIVO EVALUATION OF RAPID RELEASE AND SUSTAINED-RELEASE GELUCIRE CAPSULE FORMULATIONS [J].
DENNIS, AB ;
FARR, SJ ;
KELLAWAY, IW ;
TAYLOR, G ;
DAVIDSON, R .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1990, 65 (1-2) :85-100
[10]  
FLASHNERBARAK M, 2002, Patent No. 2002000204